Methylene Blue Composition Stability Without pH Adjusters
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge in pharmaceutical manufacturing is to create a stable and safe methylene blue composition with higher impurity levels than existing methods, while avoiding the drawbacks of traditional pH adjusters that can lead to chemical instability and microbial growth, particularly in parenterally administered products.
Innovation Solution
A sterile aqueous pharmaceutical composition of methylene blue with an Azure B impurity content between 2% and 3% and a pH below 4.0, containing elevated metal content above 20 ppm, is developed, eliminating the need for pH adjusters and using a process involving dissolving methylene blue in water, filtering, and terminal sterilization in glass containers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If traditional pH adjusters are incorporated into methylene blue composition, then pH control is improved, but chemical stability deteriorates and microbial growth risk increases
Solution Approach 1:
The patent removes pH adjusters from the methylene blue composition entirely, relying on the inherent properties of methylene blue and water to maintain physiological pH without adding external pH-controlling agents, thereby eliminating the risks of chemical reactions and microbial growth associated with pH adjusters
Solution Approach 2:
The methylene blue compound itself serves to maintain appropriate pH levels through its inherent chemical properties, eliminating the need for separate pH adjusters and their associated risks while maintaining composition stability
2Ease of manufacture
If higher Azure B impurity content (2-3%) is accepted in methylene blue, then manufacturing cost and complexity are reduced, but product purity deteriorates
Solution Approach 1:
The patent establishes a specific Azure B impurity range (2-3%) that balances manufacturing feasibility with product efficacy, recognizing that complete elimination of impurities is unnecessary and potentially harmful, while controlled impurity levels maintain both manufacturability and therapeutic effectiveness
Solution Approach 2:
The patent accepts certain levels of Azure B impurity (2-3%) as beneficial or at least acceptable, recognizing that complete purification may be unnecessarily costly and complex, and that controlled impurity levels do not compromise therapeutic effectiveness for methemoglobinemia treatment
3Ease of manufacture
If metal content is increased above 20 ppm, then manufacturing process simplicity is improved, but risk of metal contamination increases
Solution Approach 1:
The patent establishes a specific metal content threshold (>20 ppm) that reflects practical manufacturing conditions without requiring excessive purification steps, balancing the simplicity of using standard metallic equipment against the need to limit metal contamination to levels that do not compromise patient safety
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition maintains stability and safety with higher impurity levels, ensuring effective treatment of conditions like methemoglobinemia without the risks associated with pH adjusters, and demonstrates stability and efficacy over six months under controlled storage conditions.
Implementation Method 1
Methylthioninium chloride, also known as methylene blue or, 3,7-bis-(dimethylamino)-phenothiazin-5-ium chloride, is an oxidation-reduction agent used for the treatment of patients with acquired methemoglobinemia
Data Source
AI summary
A sterile aqueous pharmaceutical composition contains methylene blue as active ingredient and water, wherein an Azure B impurity content of the composition ranges from 2.0 wt. % to 3.0 wt. %, a pH of the composition is below 4.0, and a total metal content of the pharmaceutical composition is above 20 ppm.